KR102615099B1 - 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 - Google Patents
아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 Download PDFInfo
- Publication number
- KR102615099B1 KR102615099B1 KR1020207000305A KR20207000305A KR102615099B1 KR 102615099 B1 KR102615099 B1 KR 102615099B1 KR 1020207000305 A KR1020207000305 A KR 1020207000305A KR 20207000305 A KR20207000305 A KR 20207000305A KR 102615099 B1 KR102615099 B1 KR 102615099B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- alkoxy
- substituted
- cyano
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517204P | 2017-06-09 | 2017-06-09 | |
| US62/517,204 | 2017-06-09 | ||
| PCT/US2018/036627 WO2018227061A1 (en) | 2017-06-09 | 2018-06-08 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200014895A KR20200014895A (ko) | 2020-02-11 |
| KR102615099B1 true KR102615099B1 (ko) | 2023-12-15 |
Family
ID=62751597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207000305A Active KR102615099B1 (ko) | 2017-06-09 | 2018-06-08 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11124494B2 (enExample) |
| EP (1) | EP3634956B1 (enExample) |
| JP (1) | JP7088965B2 (enExample) |
| KR (1) | KR102615099B1 (enExample) |
| CN (1) | CN110997653B (enExample) |
| ES (1) | ES2874352T3 (enExample) |
| WO (1) | WO2018227061A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| EP4196471A1 (en) * | 2020-08-12 | 2023-06-21 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
| WO2024220487A1 (en) * | 2023-04-18 | 2024-10-24 | Bristol-Myers Squibb Company | Carbocyclic phenylpyrrolidinone urea fpr2 agonists |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063113A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57036B1 (sr) | 2013-11-28 | 2018-05-31 | Kyorin Pharmaceutical Co Ltd | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1) |
| CN107848962B (zh) | 2015-05-27 | 2021-04-09 | 杏林制药株式会社 | 脲衍生物或其药理学上可接受的盐 |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) * | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
-
2018
- 2018-06-08 JP JP2019568054A patent/JP7088965B2/ja active Active
- 2018-06-08 EP EP18734731.5A patent/EP3634956B1/en active Active
- 2018-06-08 CN CN201880050608.1A patent/CN110997653B/zh active Active
- 2018-06-08 ES ES18734731T patent/ES2874352T3/es active Active
- 2018-06-08 US US16/619,965 patent/US11124494B2/en active Active
- 2018-06-08 KR KR1020207000305A patent/KR102615099B1/ko active Active
- 2018-06-08 WO PCT/US2018/036627 patent/WO2018227061A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063113A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634956B1 (en) | 2021-04-07 |
| ES2874352T3 (es) | 2021-11-04 |
| CN110997653A (zh) | 2020-04-10 |
| JP2020523331A (ja) | 2020-08-06 |
| CN110997653B (zh) | 2023-06-06 |
| US11124494B2 (en) | 2021-09-21 |
| KR20200014895A (ko) | 2020-02-11 |
| JP7088965B2 (ja) | 2022-06-21 |
| EP3634956A1 (en) | 2020-04-15 |
| US20210078971A1 (en) | 2021-03-18 |
| WO2018227061A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102615099B1 (ko) | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| KR102615095B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 효능제 | |
| JP7094989B2 (ja) | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト | |
| JP2021516240A (ja) | フェニルピロリジノンホルミルペプチド２受容体アゴニスト | |
| JPH07121945B2 (ja) | ピラゾロピリミジノン抗狭心症薬 | |
| JP5002592B2 (ja) | うつ病およびストレス疾患のためのアジノンおよびジアジノンｖ３阻害剤 | |
| JP4740116B2 (ja) | 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト | |
| RU2127732C1 (ru) | Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы | |
| JP7093468B2 (ja) | ４－ピラジン－２－イルメチル－モルホリン誘導体および医薬としてのその使用 | |
| KR20250172673A (ko) | 카르보시클릭 페닐피롤리디논 우레아 fpr2 효능제 | |
| CN120957970A (zh) | 碳环苯基吡咯烷酮脲fpr2激动剂 | |
| KR20250175328A (ko) | 피롤리디논 우레아 fpr2 효능제 | |
| WO2024220482A1 (en) | Pyrrolidinone urea fpr2 agonists | |
| CN120936594A (zh) | 吡咯烷酮脲fpr2激动剂 | |
| KR20250172674A (ko) | 피롤리디논 우레아 fpr2 효능제 | |
| JP7093469B2 (ja) | ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用 | |
| EP4385979A1 (en) | Multicyclic inhibitors of nav1.8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200106 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210607 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230509 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230916 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231213 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231213 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |